YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Rising global bond yields are putting pressure on high growth stories, which makes reliable Australian healthcare stocks look more interesting. Investors are paying closer attention to sectors where earnings often depend less on credit con…
Australian inflation accelerated to 4% in August, and interest rates now sit at a 15 year high of 4.6%. That mix is putting cost pressure on households while lifting the appeal of resilient sectors. Healthcare often holds up when budgets t…
With Australian interest rates now at a 15-year high, cheap debt no longer does the heavy lifting for corporate performance. Investors are paying closer attention to who is actually steering each business. Founder led Australian companies,…
Bond yields at two decade highs have reset borrowing costs across the globe, which puts pressure on heavily indebted businesses but shines a spotlight on Australian companies that can fund their own expansion. When insiders own meaningful…
Global bond yields are climbing, and central banks are tightening policy to keep inflation in check. That raises the bar for every listed company. Founder led Australian businesses can be different because leaders often have more of their…
Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index increasing 0.9 PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Mesoblast Limited NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received approval from the Unite…
[Scientists inside a laboratory] Hinterhaus Productions The Food and Drug Administration and Duke-Margolis Institute for Health Policy will convene a public workshop this month to examine one of the most difficult questions in rare disease…
Mesoblast Limited RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:ME…
Key Points Interested in Mesoblast Limited? Here are five stocks we like better. RYONCIL generated $115 million in fiscal 2026 revenue, its first full year of commercial sales, while Mesoblast reduced its net loss by 44% to $57.5 million.…
Central banks are weighing possible further rate hikes to keep inflation in check, which keeps pressure on weaker balance sheets and slower growth stories. Healthy high growth potential stocks can look more attractive in this kind of rate…
Mesoblast Limited NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and fin…
Mesoblast Limited MESO announced that it has completed patient treatment in a pivotal phase III MSB-DR004 study, evaluating its pipeline candidate, rexlemestrocel-L, for treating chronic low back pain (CLBP) caused by the inflammatory cond…
Healthcare stocks were mixed Monday afternoon, with the NYSE Healthcare Index up nearly 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) fractionally lower.The iShares Biotechnology ETF (IBB) climbed up 1.8%.In corporate…
Mesoblast Limited NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment in th…
Mesoblast Limited Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back Pain Activity Report for…
Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back Pain Activity Report for Quarter Ended June…
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage…
Mesoblast Limited NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 3…
NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treate…
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.03%, and the actively tr PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Mesoblast Limited Continued Growth Underpins First Full Year Net Revenue of US$115M NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory disea…
NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net revenue of US$36 million for…
Mesoblast Limited NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License Appl…
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License Application (BLA) fili…
Optimized capital structure, retiring short-term maturing debt Well-funded for commercial operations and growth pipeline NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cell…
Mesoblast Limited Optimized capital structure, retiring short-term maturing debt Well-funded for commercial operations and growth pipeline NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader…
In the midst of a challenging period for Australian shares, with market sentiment swayed by geopolitical tensions and economic uncertainties, investors are increasingly on the lookout for opportunities in undervalued stocks. Identifying st…
As Australian shares rebound from a significant market downturn, driven by global events and domestic fiscal policies, investors are keenly observing the landscape for opportunities. In this environment, growth companies with high insider…
Australian shares are poised for a slight retreat, influenced by Wall Street's recent cooling and ongoing global economic discussions. Despite the fluctuating market conditions, penny stocks—often overlooked due to their smaller size or ne…
The Australian share market is experiencing a downturn, influenced by the recent budget announcement and external pressures such as rising U.S. inflation, which has caused some uncertainty among investors. In this environment, identifying…
Mesoblast Limited recently announced it has completed patient recruitment for its pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain due to degenerative disc disease, a placebo-controlled study following at least 300 patien…
* Mesoblast press release [https://seekingalpha.com/pr/20493892-mesoblast-reports-ryoncil-net-revenues-of-us-30_3m-and-improved-net-operating-cash-spend-for] (MESO [https://seekingalpha.com/symbol/MESO]): Q1 Ryoncil® gross sales for the qu…
Mesoblast Limited Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:…
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), gl…
As the Australian market faces its seventh consecutive day in the red, with inflation expected to spike to nearly three-year highs, investor sentiment has turned bearish. Despite these challenging conditions, penny stocks remain a relevant…